Venus Remedies Announces Q1 FY27 Financial Results and Approves Revisions to Memorandum of Association
Venus Remedies Limited released its unaudited financial results for the quarter ended June 30, 2026, alongside announcing the Board’s approval of key revisions to the company's Memorandum of Association (MOA). The outcomes reflect the company's ongoing operations in the pharmaceutical sector and highlight strategic investments involving its subsidiaries.The results were reviewed by independent auditors and are available for review. Key operational updates provided during the meeting held on July 20, 2026, focused on the performance of both standalone and consolidated entities.
Financial Performance Summary
The company reported the following unaudited financial results (in ₹ Crores) for the quarter ended June 30, 2026:Consolidated Financial Results
| Particulars | Q Ended 30/06/2026 (Unaudited) | Q Ended 31/03/2026 (Audited) | Q Ended 30/06/2025 (Unaudited) | Q Ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 178.86 | 259.40 | 137.18 | 769.60 |
| Total Income | 181.48 | 264.35 | 140.59 | 782.18 |
| Total Expense | 151.44 | 202.74 | 127.99 | 648.02 |
| Profit before taxes | 30.04 | 61.61 | 12.60 | 134.16 |
| Net Profit/(Loss) for the period | 22.97 | 47.49 | 9.60 | 102.78 |
| Total Comprehensive Income | 28.88 | 42.00 | 11.95 | 102.80 |
Standalone Financial Results
| Particulars | Q Ended 30/06/2026 (Unaudited) | Q Ended 31/03/2026 (Audited) | Q Ended 30/06/2025 (Unaudited) | Q Ended 31/03/2026 (Audited) |
|---|---|---|---|---|
| Revenue from Operations | 178.80 | 250.01 | 137.13 | 768.73 |
| Total Income | 181.35 | 263.64 | 139.85 | 780.19 |
| Total Expense | 206.08 | - | 125.16 | - |
| Profit before taxes | 32.60 | 57.57 | 14.70 | 130.67 |
| Net Profit/(Loss) for the period | 25.53 | 43.45 | 11.70 | 99.31 |
Revisions to Memorandum of Association Approved by Board
The Board of Directors approved certain revisions to the proposed alteration of the Memorandum of Association (MOA). These changes are intended primarily to align the company's Object Clause with the provisions of the Companies Act, 2013, and to update the Main Objects and ancillary objects in line with current business practices. The updates clarify the company's objectives and business scope within the pharmaceutical sector.The revised MOA will be presented before the members for approval by way of a Special Resolution at the ensuing 37th Annual General Meeting (AGM). The revisions include expanded clauses detailing activities such as research, development, manufacturing, distribution, and establishing international operations to support the company's objectives.
Strategic Investment Update
The board meeting provided clarity regarding the investment in Venus Pharma GmbH, a wholly owned subsidiary of the company located in Germany. The results show that there is outstanding share application money amounting to INR 2,859.72 Lakhs related to this subsidiary. This allotment has been pending as it is not mandatory under applicable German laws.Management stated that they view the investment as strategic and reiterated their intention to provide financial and operational support during the transition period as part of ongoing restructuring of European operations planned for FY 2026-27, aiming for recovery of the funds in due course.
HARDWYN Stock Price Movement
Shares of Hardwyn India Limited slipped by 2.66% in trading today, ultimately settling at ₹15.61 following a volatile session. The stock traded within an intraday range of ₹15.21 to ₹16.38 and saw total volume reach approximately 2.50 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: